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Background: The objective of this study is to investigate symptoms, clinical factors and socio-demographic factors associated
with colorectal cancer (CRC) diagnosis and time to diagnosis.
Methods: Prospective cohort study of participants referred for suspicion of CRC in two English regions. Data were collected using
a patient questionnaire, primary care and hospital records. Descriptive and regression analyses examined associations between
symptoms and patient factors with total diagnostic interval (TDI), patient interval (PI), health system interval (HSI) and stage.
Results: A total of 2677 (22%) participants responded; after exclusions, 2507 remained. Participants were diagnosed with CRC
(6.1%, 56% late stage), other cancers (2.0%) or no cancer (91.9%). Half the cohort had a solitary first symptom (1332, 53.1%); multiple
first symptoms were common. In this referred population, rectal bleeding was the only initial symptom more frequent among
cancer than non-cancer cases (34.2% vs 23.9%, P¼ 0.004). There was no evidence of differences in TDI, PI or HSI for those with
cancer vs non-cancer diagnoses (median TDI CRC 124 vs non-cancer 138 days, P¼ 0.142). First symptoms associated with shorter
TDIs were rectal bleeding, change in bowel habit, ‘feeling different’ and fatigue/tiredness. Anxiety, depression and gastro-
intestinal co-morbidities were associated with longer HSIs and TDIs. Symptom duration-dependent effects were found for rectal
bleeding and change in bowel habit.
Conclusions: Doctors and patients respond less promptly to some symptoms of CRC than others. Healthcare professionals should
be vigilant to the possibility of CRC in patients with relevant symptoms and mental health or gastro-intestinal comorbidities.
Colorectal cancer (CRC) is the third most common cancer world
wide and the United Kingdom’s fourth commonest (Cancer
Research UK). Despite the introduction of screening programmes
in many countries, most cases present symptomatically. Although
5-year survival rates for CRC have improved to over 60% in the last
decade, CRC patients in the United Kingdom continue to have
poorer survival rates than those in comparable countries (Coleman
et al, 2011; Allemani et al, 2015). This may partly be due to longer
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intervals between the onset of cancer symptoms and the patient’s
presentation to healthcare, compounded by unequal access to
optimal diagnostics and specialist care, leading to more late-stage
diagnoses (Neal and Allgar, 2005; Maringe et al, 2013). There are
also gender, age and region differences in time to diagnosis across
the United Kingdom (Din et al, 2015).
The diagnostic process comprises a series of stages or intervals,
each contributing to the overall period of time between onset of
symptom/s and initiation of treatment (Weller et al, 2012). The total
diagnostic interval (TDI) comprises the patient interval (PI – from
first symptom onset to first healthcare consultation) and the health
system interval (his – from first consultation via referral and
investigations to diagnosis and initiation of treatment) (Weller et al,
2012): shorter PIs and HSIs are associated with improved CRC
prognoses (Torring et al, 2011; Neal et al, 2015). For CRC, recent
evidence suggests that both intervals are longer than for other
common cancers such as lung or urological cancer (Dregan et al,
2013; Keeble et al, 2014; Neal et al, 2014a; Lyratzopoulos et al, 2015b).
Colorectal cancer patients may be symptomatic for many
months before presentation. They may experience multiple
symptoms, both bowel-specific (rectal bleeding, change in bowel
habit and abdominal pain) and systemic (loss of weight or appetite
and fatigue) (Hamilton et al, 2005; Rasmussen et al, 2015). Not all
individuals interpret their initial symptoms as serious and may
attribute them to normal variation, ageing, lifestyle or other
comorbidities (Macleod et al, 2009; Hall et al, 2015; McLachlan
et al, 2015). International comparisons suggest that lower age-
related risk and highest perceived barriers to symptomatic
presentation were reported in the United Kingdom (Forbes et al,
2013); other potential influences include negative beliefs about
cancer outcomes (Beeken et al, 2011; Lyratzopoulos et al, 2015a)
and poor awareness of the risk of cancer (Simon et al, 2010; Quaife
et al, 2014).
Once the decision to seek medical help has been made, further
delays may occur. One third of CRC patients have three or more
consultations with a general practitioner (GP) before referral,
compared with only 17.9% for all cancers (Lyratzopoulos et al,
2013). Furthermore, the pathway to diagnosis in primary care may
be complex, with delays arising when presentation is complicated
by comorbid conditions, when referral is delayed or declined, or
from false-negative investigation (Rubin et al, 2014).
Symptoms of possible CRC much more commonly arise from
benign or self-limiting conditions and GPs face a considerable
challenge to evaluate patients while making efficient use of hospital-
based resources (Hansen et al, 2015). Much of the evidence about
the predictive value of symptoms for cancer or their association with
later diagnosis comes from retrospective studies of people with CRC
(Esteva et al, 2013) or from general practice data sets (Hamilton
et al, 2005); these are limited by quality of data recording. Little is
known about the diagnostic pathways of those whose symptoms
transpire not to be caused by CRC or about which symptoms are
associated with less timely diagnosis. We therefore recruited a
prospective cohort of patients with symptoms suggestive of CRC at
the point of their referral. We aimed to investigate the symptoms,
clinical factors and socio-demographic factors associated with CRC
diagnosis and time to diagnosis.
MATERIALS AND METHODS
Setting and governance. We recruited patients from four
secondary care hospitals in the East (n¼ 1) and North East of
England (n¼ 3) between December 2010 and March 2013. We
gained all appropriate NHS ethics (reference: 10/H0306/50) and
clinical governance approvals. The SYMPTOM colorectal study
was conducted alongside the SYMPTOM lung and pancreas
studies, collectively part of the NIHR-funded DISCOVERY
programme of applied research. The methods of data collection
and analysis have already been described with the reporting of the
SYMPTOM lung study (Walter et al, 2015) and hence will only be
outlined briefly here.
Patient recruitment. All GP referral letters to urgent and routine
colorectal and gastrointestinal clinics in participating hospitals
were reviewed by a research nurse, to identify patients aged X40
years whose referral mentioned any one or more symptoms from a
pre-specified list of symptoms known to be associated with CRC
(Supplementary Material). These patients were sent an information
sheet, the SYMPTOM colorectal questionnaire and a reply-paid
envelope for return. Patients were not eligible for the study if they
were already undergoing treatment for any cancer (excluding non-
melanotic skin cancer) or had such serious mental and/or physical
disease that they were not considered suitable to complete a
questionnaire, based on review of the medical record by the
research nurse. Patients referred as a result of participation in the
Bowel Cancer Screening Programme were excluded. No reminder
letters were sent to non-responders, as required by the research
ethics committee.
Data collection. We based our data collection, analysis and
reporting on the Aarhus statement for the conduct of cancer
diagnostic studies and STROBE guidelines for reporting observa-
tional studies (von Elm et al, 2007; Weller et al, 2012).
Patient data. Patient data were collected using the SYMPTOM
questionnaire, completed and returned to the research team within
3 months of being sent; most completed it within 2 weeks and
before receiving their diagnosis. The SYMPTOM colorectal
questionnaire was derived from the previously validated C-SIM
questionnaire (Neal et al, 2014b). This had been developed for use
among people recently diagnosed with cancer and hence we
modified it for use before diagnosis, consulting widely with clinical
and research colleagues, and patient representatives, to ensure it
was worded sensitively, as cancer may not have been explicitly
mentioned as a possibility by the referring GP. The questionnaire
asked for the first symptom noticed by the participant and then
sought the presence or absence of specific symptoms
(Supplementary Material). The remaining sections contained items
about other symptoms and patient factors, including demographic
characteristics and comorbidities.
Primary care data. Participants’ GPs completed a short proforma
from the patient’s clinical record, including dates of the first
presentation with any symptom from the questionnaire within the
previous 2 years, plus its duration, if recorded.
Hospital data. We extracted data from hospital medical records on
the following: date and type of referral (urgent, routine, emergency
and other); date of first specialist consultation; dates of investigations
and their findings; date of diagnosis (histological and clinical); and
dates of MDT meetings and their clinical decisions. Data extraction
took place a minimum of 6 months after recruitment, to allow
sufficient time for completion of investigation and initiation of
treatment. We undertook double data abstraction of a 5% sample of
selected hospital data (dates of referral, first appointment, diagnosis
and stage) and confirmed an acceptable level of agreement (480%
for dates, 490% for diagnosis and stage, Cohen’s k40.75 for all),
with any discrepancies generally minor.
Data handling
Clinical outcomes. We used the date on the first confirmatory
histology report as the date of diagnosis when this was available for
both cancer (ICD codes C18-C20) and non-malignant conditions
(Weller et al, 2012). Otherwise, we used the first date of the clinical
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diagnosis in the hospital medical record. Participants were
classified into three groups: those with primary CRC (CRC), other
intra-abdominal cancer (OC) and no cancer (NC). The main
analyses focused on CRC vs NC, with secondary analyses including
all cancers (CRC plus OC) vs NC. Colorectal cancer staging was
categorised using TNM status at diagnosis (Travis et al, 2012) and
further categorised into early stage (stages I and II) and late stage
(stages III and IV). Complex diagnoses, or cases with incomplete
data, were agreed by an adjudication group of clinicians associated
with the study (FW, JE, GR and MR).
Demographic and clinical variables. Demographic details
included the following: gender; age (treated as a continuous
variable); ethnicity (coded as White vs non-White); smoking status;
educational status; occupational status; living alone; and postal
code, used to assign groups to quintiles of the Index of Multiple
Deprivation (1 ‘least deprived’ to 5 ‘most deprived’). Clinical
variables relating to comorbidities included the following: gastro-
intestinal disease (inflammatory bowel disease, irritable bowel
syndrome and peptic ulcer); respiratory disease (chronic obstruc-
tive pulmonary disease/asthma/other lung disease), anxiety/
depression, heart disease, diabetes and arthritis. Family history of
cancer was also identified (present vs absent).
Symptoms. All symptoms reported up to 2 years before diagnosis
were entered into the analysis (symptoms of longer than 2 years
duration were unlikely to be associated with the subsequent
diagnosis) (Hamilton et al, 2005; Biswas et al, 2015). Where
participants provided estimated dates, these were converted to
exact dates by adapting an algorithm used in the C-SIM trial (Neal
et al, 2014b; Walter et al, 2015). We used exact dates where
available and estimated dates otherwise. Furthermore, if a
participant’s unprompted, or free text, first symptom matched
their response to a question about specific symptoms, they were
given the corresponding symptom code and the earlier date. A first
symptom was thus identified for each participant. Many
participants reported more than one first symptom, termed
‘multiple first symptoms’. ‘Subsequent symptoms’ were defined
as any symptom occurring after a first symptom and before
diagnosis.
The TDI. The TDI, or ‘time to diagnosis’, was defined as the time
from onset of the first symptom/s to the date of diagnosis. Where
the date of first presentation to healthcare was known, the PI,
defined as the time from first symptom/s to the first presentation,
and the HSI, defined as the time from first presentation to
diagnosis, were also calculated.
Analysis. Descriptive analyses were performed on all demographic,
clinical and symptom data for the group as a whole and by
diagnostic group (CRC, all cancer (CRC plus OC) and NC). The
CRC group was also sub-analysed by stage at diagnosis. The TDI
and PI for each group was compared using Wilcoxon rank-sum test.
Clinically relevant demographics, comorbidities, first symptom/s
and family history of cancer variables were a priori included in
multivariate analyses, to identify predictors of time to diagnosis.
Variables present in fewer than 10 participants were excluded. We
chose to analyse CRC, OC and NC groups together for all
outcomes, because at the time of presentation and referral the final
diagnosis was unknown. Flexible parametric survival models were
used to model the TDI, the PI and the HSI. In these cases, rather
than death, the event considered to be ‘failure’ in the survival
model is either first presentation to healthcare or diagnosis as
appropriate. We preferred flexible parametric survival models
(Lambert and Royston, 2009) over the Cox model, as they allow the
investigation of duration-varying effects. We present results from
two models: first, with only time-constant effects and, second, one
that allows for duration-varying effects for symptoms. The former
model provides average hazard ratios over time for all variables
similar to a Cox model and makes it easier to compare the effects
of different factors. The second model allows us to examine in
more detail how their effect varies with duration. Symptoms with
duration-varying effects were identified using a forward selection
approach described in Royston and Lambert (2011) and using a
significance level of Pp0.01. All models used splines with five
degrees of freedom for the baseline hazard; the duration-dependent
effects were modelled using two degrees of freedom for the TDI
and HSIs, and three degrees of freedom for the PIs.
Sample size. The expected total number of cases in the 2 areas was
265 annually. Assuming half of these could be identified
prospectively from fast track and routine referrals including via
colonoscopy (Barrett and Hamilton, 2008), we needed to recruit
for 2 years to achieve 200 participants with CRC. We estimated one
patient in 25 would have CRC (6–11% in 2-week wait clinics
(Rai and Kelly, 2007), but lower out with these clinics). With 200
participants with CRC and at least 10 times as many without we
would have over 80% power to detect and OR41.52 for a common
symptom occurring in half of participants. With the same 2200
patients, all of which having a TDI, we would expect to have 80%
power to detect an HR41.23 for a symptom occurring in 10% of
patients.
RESULTS
Patients (12 236) were approached and 2667 responded, an overall
21.8% response rate (East 26.3% and North East 18.6%). Of these,
70 did not meet the eligibility criteria and a further 90 had
insufficient data for analysis, leaving a final cohort of 2507
participants. The demographics of the responders were similar to
those of non-responders (responders 47% male, median age 65
years; non-responders 45% male, median age 65 years). The stage
distribution for those of our cohort who had CRC was comparable
to 2013 data for England (late stage 50% vs early 40% and 10%
unknown) (National Cancer Intelligence Network (NCIN)).
The characteristics of the whole cohort are provided in Tables 1
and 2. Participants were diagnosed with CRC (152, 6.1%; 56% late
stage), other cancers (50, 2.0%) or no cancer (2305, 91.9%). The
majority of those with CRC had late-stage disease (n¼ 85, 55.9%;
early stage: n¼ 65, 42.8%); two CRCs (1.3%) were unstaged. The
proportion of males was higher in the group diagnosed with CRC
compared with the group diagnosed with NC (57.2% vs 46.2%,
P¼ 0.008). Those in the CRC group also had a higher median age
(71 vs 65, Po0.001) and were more likely to have been referred
through an urgent pathway (90.1% vs 71.1%, Po0.001). The
diagnostic groups were otherwise similar in terms of deprivation,
education and ethnicity (Table 2).
Among the total cohort, over half had a solitary first symptom
(1332, 53.1% (CRC 92, 60.5%, NC 1218, 52.8%)). However,
multiple first symptoms were common with 21.6% having two first
symptoms, 9.3% having three and 8.4% with four or more multiple
first symptoms. A few participants (7.6%) reported no symptoms
first appearing within 2 years of diagnosis (most had symptom/s
pre-dating the 2-year cut-off). Across the total cohort, change in
bowel habit (62.8%) and ‘bleeding from back passage’ (37.8%) were
the most common symptoms, but only 45% and 24.4% of those,
respectively, were reported as first symptoms (Table 3). Symptoms
not specifically enquired for in the questionnaire but volunteered,
such as acute gastro-intestinal illness, perianal pain, flatulence,
bloating and mucus discharge, were individually reported byo3%
of participants. ‘Bleeding from back passage’ was significantly
more frequently reported in people diagnosed with CRC than
non-cancer as a first symptom (34.2% vs 23.9%, P¼ 0.004).
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No other symptom as a first or subsequent symptom was more
common in those with CRC than those without.
A TDI could be calculated for 2316 participants; the median
TDI across the whole cohort was 136 days (IQR 74–255) (Table 4).
There was no difference in the TDI between people diagnosed with
CRC and NC (CRC 124 vs NC 138 days, P¼ 0.142), and no
evidence of differences between PI and HSI among those with and
without CRC (PI median 41 days vs 36 days, P¼ 0.606; HSI 49
days vs 59 days, P¼ 0.078).
Results from the time constant survival models are shown in
Table 5 (Supplementary Table A1 for univariate analyses). Older age
at diagnosis and a number of symptoms were all associated with a
shorter TDI, while gastrointestinal comorbidity, depression/anxiety
and family history of cancer were all associated with a longer TDI
and HSI.
Symptom duration-dependent effects. We found symptom
duration-dependent effects for ‘bleeding from back passage’ and
change in bowel habit (Supplementary Figure 1). The time-
constant effects from other variables in the same model are
similar to those described in the previous section and are not
detailed here. The symptom ‘bleeding from back passage’ was
associated with briefer PI and HSI initially (HR41), but as
the duration of this symptom lengthened the association
weakened (HR became close to 1). In other words, when this
symptom was present it was associated with faster action
(presentation to healthcare professional and/or referral) in the
initial period following symptom onset or presentation, compared
with other symptoms, but if initial action was not taken the existence
of the symptom had little impact on action at later times. In contrast,
a change in bowel habit was associated with a lengthier PI initially
(HRo1) but if the symptom persisted beyond 10 days it became
associated with a briefer PI (HR41). In other words, those whose
initial symptom was a change in bowel habit were less likely to
present early than those with other symptoms, but of those who
did not present in the first 10 days, they presented faster on average
than people with other symptoms (HR41). Change in bowel
habit was always associated with a briefer HSI, with no time-
dependent effect.
For early stage CRC, the median TDI for any first symptom was
157 days compared with 99 days for late stage CRC (P¼ 0.019)
(Table 6).
DISCUSSION
This is the first study worldwide to recruit a large prospective
cohort of patients with suspicious symptoms before diagnosis, to
study factors associated with time to diagnosis for CRC. Among
these patients, who had been referred for investigation, rectal
bleeding was the only symptom more frequently seen with CRC,
but it occurred in only a third of cases as a first symptom and less
than two-thirds at any point before diagnosis. Other so-called
‘alarm’ symptoms such as change in bowel habit were also very
common in this referred population but did not differentiate
between CRC and those without cancer. The positive predictive
value of these symptoms will be higher in this study population
than in primary care, but the odds ratio between those with and
without cancer will fall as this is an enriched, referred population.
This does not mean these symptoms should not be taken seriously.
Multiple first symptoms were common and symptoms often
evolved over time before patients sought healthcare. There were
different symptom and patient factors associated with the PI and
HSI. Some less specific symptoms such as indigestion/abdominal
pain or ‘feeling different’ were associated with shorter PIs; in
contrast, only the very specific, ‘classical’, symptoms such as
change in bowel habit and rectal bleeding were associated with
shorter HSIs.
Our novel analysis of duration-dependent effects of symptoms
showed different patient and healthcare provider responses to
certain key symptoms of CRC according to how long the patient
had, compared with other symptoms, experienced them. A short
duration of rectal bleeding for some patients triggers an early
consultation and prompt response by the healthcare system. Once
rectal bleeding has been present for a longer time, it is no more
likely than other symptoms to have a shorter diagnostic interval
despite its recognition as a classical alarm symptom. This means
that both patients and healthcare providers may normalise longer-
term rectal bleeding and not consult or investigate promptly
(Emery et al, 2013).
Comorbidities in the whole cohort were also associated with
longer total diagnostic and healthcare intervals. Importantly,
people with mental health problems, self-reported anxiety or
depression, experienced a longer TDI and HSI, suggesting that
their possible physical symptoms were not taken as seriously and
were investigated later. Similarly, gastro-intestinal comorbidity
increased time to diagnosis, probably due to healthcare providers
attributing new or worsening symptoms to pre-existing illness
(Emery et al, 2013; Hall et al, 2015).
There was no evidence that those with CRC were diagnosed
more quickly than those with an alternative diagnosis. This is
surprising given the fact that there were a higher proportion of
Table 1. Diagnostic characteristics of participants
Total (%)
Primary CRC 152 (6.1)
Other cancers 50 (2.0)
Lymphoma 9
Prostate cancer 7
Gynaecological cancer (ovarian, uterine) 7
Anal cancer 5
Renal cancer (kidney, bladder) 4
Cancer unknown primary 4
Oesophageal cancer 3
Pancreatic cancer 2
Multiple myeloma 2
Stomach cancer 2
Othera 5
Non-cancera 2305 (91.9)
Polyps 612 (26.6)
Polyp with metaplasia 200 (8.7)
Poly with dysplasia 168 (7.3)
Polyp NOS 244 (10.6)
Nil abnormal 598 (25.9)
Diverticular disease 463 (20.1)
Inflammatory bowel disease (IBD) 189 (8.2)
Colitis ulcerative 55 (2.4)
Colitis–other 99 (4.3)
Crohn’s disease 7 (0.3)
IBD NOS 28 (1.2)
Haemorrhoids 186 (8.1)
Irritable bowel syndrome 95 (4.1)
Benign gastro-duodenal disease 83 (3.6)
Miscellaneous 51 (2.2)
Anaemia (no lower GI cause found) 31 (1.3)
Hepato-pancreato-biliary disorders 20 (0.9)
Anal conditions (excluding haemorrhoids) 13 (0.6)
Constipation 13 (0.6)
Coeliac disease 5 (0.2)
Total 2507
Abbreviations: CRC¼ colorectal cancer; GI¼gastrointestinal; NOS¼not otherwise speci-
fied. Other cancers include (n¼ 1): leiomyosarcoma, appendix, peritoneal, melanoma,
cholangiocarcinoma.
aPercentages add to 4100%, because 54 patients have more than one diagnosis. More
than one diagnosis in the same category (e.g., miscellaneous) was counted only once.
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cancers using the urgent pathway and guidance on urgent referral
for suspected CRC in England recommends that ‘alarm’ symptoms
such as rectal bleeding and change in bowel habit warrant urgent
referral for investigation (NICE, 2005). Symptoms other than rectal
bleeding in this relatively large prospective cohort did not help
differentiate CRC from other diagnoses.
The median PI was 35 days and median HSI (combining
primary and secondary care) was 58 days. This contrasts with
findings of the secondary analysis of CRC data in the National
Audit of Cancer Diagnosis in Primary Care, where data from
primary care medical records showed a median PI of 19 days
(Lyratzopoulos et al, 2015b). In a separate study using the same
data set, 21% of CRC patients had three or more primary care
consultations before referral, potentially contributing to longer
HSIs (Lyratzopoulos et al, 2013). However, in an analysis of UK
General Practice Research Database data for 2962 patients with
Table 3. Symptoms reported by participants, stratified by all and first symptom/s and diagnostic group
CRC (n¼152) NC (n¼2305) Total cohort (n¼2507)
Symptom
First
symptoms
Subsequent
symptoms
First
symptoms
Subsequent
symptoms
First
symptoms
Subsequent
symptoms
P-value for
first symptoms
CRC vs NC
Symptoms in questionnaire
Change in bowel habit 66 (43.4) 27 (17.8) 1043 (45.2) 410 (17.8) 1129 (45) 446 (17.8) 0.661
‘Bleeding from back passage’ 52 (34.2) 39 (25.7) 552 (23.9) 296 (12.8) 612 (24.4) 336 (13.4) 0.004
Indigestion/heartburn/persistent tummyache 30 (19.7) 13 (8.6) 509 (22.1) 281 (12.2) 549 (21.9) 302 (12) 0.499
Fatigue or tiredness that is unusual for you 35 (23) 23 (15.1) 404 (17.5) 307 (13.3) 448 (17.9) 347 (13.8) 0.086
Feeling different ‘in yourself’ from usual 27 (17.8) 11 (7.2) 391 (17) 257 (11.1) 433 (17.3) 278 (11.1) 0.799
Decrease in appetite 15 (9.9) 16 (10.5) 195 (8.5) 192 (8.3) 220 (8.8) 221 (8.8) 0.547
Back pain 3 (2) 9 (5.9) 197 (8.5) 179 (7.8) 210 (8.4) 194 (7.7) 0.004
Unexplained weight loss 6 (3.9) 18 (11.8) 111 (4.8) 183 (7.9) 127 (5.1) 214 (8.5) 0.626
Other symptoms reported by participants
Other (non-gastro-intestinal) symptoms 4 (2.6) 3 (2) 47 (2) 16 (0.7) 53 (2.1) 20 (0.8) NA
Acute gastro-intestinal illness 0 (0) 3 (2) 48 (2.1) 15 (0.7) 49 (2) 18 (0.7) NA
Perianal pain or discomfort 2 (1.3) 1 (0.7) 37 (1.6) 15 (0.7) 39 (1.6) 16 (0.6) NA
Wind or flatulence 0 (0) 2 (1.3) 33 (1.4) 11 (0.5) 33 (1.3) 13 (0.5) NA
Urgency or leakage of bowels 0 (0) 0 31 (1.3) 13 (0.6) 32 (1.3) 13 (0.5) NA
Bloating 0 (0) 1 (0.7) 26 (1.1) 12 (0.5) 28 (1.1) 14 (0.6) NA
Mucus or discharge per rectum 0 (0) 2 (1.3) 25 (1.1) 7 (0.3) 25 (1) 9 (0.4) NA
Pain, non-abdominal 1 (0.7) 0 22 (1) 9 (0.4) 23 (0.9) 9 (0.4) NA
Abbreviations: CRC¼ colorectal cancer; NA¼ not applicable; NC¼ no cancer. Values are n (%), unless otherwise stated, and all columns add up to 4100% because of multiple symptoms.
Table 2. Socio-demographic characteristics of participants
CRC (n¼152) OC (n¼50) NC (n¼2305) Total cohort
(n¼2507)
P-value
CRC vs NC
Age (median, range) 71 (40–92) 71.5 (51–91) 65 (40–100) 65 (40–100) o0.001
Gender
Male 87 (57.2) 30 (60) 1064 (46.2) 1181 (47.1) 0.008
Female 65 (42.8) 20 (40) 1241 (53.8) 1326 (52.9)
Highest education level
Degree/diploma/equivalent 67 (44.1) 17 (34.0) 941 (40.8) 1025 (40.9) 0.511
A level/GCSE/O level 42 (27.6) 16 (32.0) 740 (32.1) 798 (31.8)
Other/none/missing 43 (28.3) 17 (34.0) 624 (27.1) 684 (27.3)
Ethnicity
White 149 (98.0) 50 (100) 2259 (98.0) 2458 (98.1) 0.640
Other/missing 3 (2.0) 0 46 (2.0) 49 (2.0)
Smoking status
Current 16 (10.5) 2 (4.0) 205 (8.9) 223 (8.9) 0.549
Ex-smoker 68 (44.7) 21 (42.0) 970 (42.1) 1059 (42.2)
Never/missing 68 (44.7) 27 (54.0) 1130 (49.0) 1225 (48.9)
Lives alone
Yes 43 (28.3) 14 (28.0) 538 (23.3) 595 (23.7) 0.164
No/missing 109 (71.8) 36 (72.0) 1767 (76.7) 1912 (76.3)
Deprivation (IMD quintiles)
First national quintile (least) 61 (40.1) 13 (26.0) 826 (35.8) 900 (35.9) 0.168
Second national quintile 40 (26.3) 12 (24.0) 550 (23.9) 602 (24.0)
Third national quintile 12 (7.9) 10 (20.0) 352 (15.3) 374 (14.9)
Fourth national quintile 20 (13.2) 10 (20.0) 304 (13.2) 334 (13.3)
Fifth national quintile (most) 19 (12.5) 5 (10.0) 263 (11.4) 287 (11.4)
missing 0 0 10 (0.4) 10 (0.4)
Abbreviations: CRC¼ colorectal cancer; IMD¼ Index of Multiple Deprivation; OC¼other cancer; NC¼ no cancer. Values are n (%), unless otherwise stated. Missing values were included in the
Other/Never categories where possible. Percentages are as follows: Employment Status (2.0), Education Level (3.3), Ethnicity (0.8), Smoking Status (1.5), Live Alone (0.6), referral route (2.2).
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CRC in 2007/8, the median HSI, of 80 days, was more comparable
to our own findings (Neal et al, 2014a).
Key strengths of this study were the prospective design and
the collection of data from several sources: patient reports and
primary care and specialist records. The analytical and reporting
approaches were robust and performed according to the
methodological approaches and definitions recommended in the
Aarhus statement (Weller et al, 2012) and STROBE guidelines
(von Elm et al, 2007). We chose to define the date of first
symptom/s using the patient-reported date rather than the primary
care-reported date, as we were analysing patient-reported
symptom/s. Ideally, a study would recruit patients from primary
care before referral; however, this would be accompanied by major
logistical and resource implications in identifying an extremely
large prospective cohort of patients with colorectal symptoms, to
capture sufficient patients with cancer. Instead, we recruited
patients when they first encountered secondary care; this had the
added benefit of allowing us to recruit patients presenting as
emergencies and those referred from other specialists. Recruitment
involved two regions of England, selected to ensure a broad range
of socio-economic, educational and occupational levels, and the
deprivation data suggest that the cohort was reasonably repre-
sentative of the national population.
The main study limitation is the overall recruitment rate of 22%,
although this is similar to other recent studies (Kidney et al, 2015;
Walter et al, 2015). We sought to make contact with the target
population before they underwent investigation and received a
diagnosis, and it is possible that some were unable or unwilling to
complete a questionnaire at this worrying time. We are also likely
to have under-recruited people who presented as an emergency or
who died soon after presentation. However, a recent study from the
English Cancer Patient Experience Study showed that only 6% of
eligible patients died between sampling and mail-out, suggesting
potential survival bias in these types of study is relatively small
(Abel et al, 2016). The demographics of non-responders were
very similar to participants and the proportion of late-stage CRC
was comparable to national data, suggesting our cohort was
reasonably representative, that selection bias was not a major
issue, and that the findings can be generalised to similar
symptomatic populations. If sicker patients were less likely to
take part in the study and they were more likely to have shorter
intervals, we may have overestimated the typical intervals
in the population. We may well have also underestimated
differences between those with different presenting symptoms.
In common with a Danish prospective population-based study of
diagnostic intervals, the problem of confounding by indication
remains to some extent (Torring et al, 2012). Our results did not
find that shorter time to diagnosis was associated with earlier
stage disease. It may be that late-stage disease has different
symptom profiles, which affect help-seeking and use of diagnostic
pathways. Tumour factors (such as histological type, rate of
growth and location) and host factors (such as comorbidity) can
influence diagnostic intervals and result in apparently earlier
diagnosis of later stage disease. As our study set out to investigate
the diagnostic intervals from perception of first symptom to
diagnosis, our primary exposure was the initial symptom or
Table 4. TDI, PI and HSI for first symptom/s for total cohort and by diagnostic groups
Total cohort CRC NC
Symptom Median (IQR) n Median (IQR) n Median (IQR) n
(A) TDIa
Any symptom 136 (74–255) 2316 124 (74–226) 149 138 (74–264) 2120
Change in bowel habit 113 (69–203) 1129 124 (66–226) 66 112 (70–203) 1043
‘Bleeding from back passage’ 90 (49–164) 612 88 (47–142) 52 89 (49–173) 552
Indigestion/heartburn/persistent tummy ache 139 (81–277) 549 125 (80–262) 30 142 (81–283) 509
Fatigue or tiredness that is unusual for you 143 (86–239) 448 130 (92–189) 35 146 (86–247) 404
Feeling different ‘in yourself’ from usual 128 (77–216) 433 124 (80–154) 27 130 (76–231) 391
Decrease in appetite 115 (69–235) 220 98 (64–138) 15 115 (69–269) 195
Back pain 161 (79–294) 210 98 (92–525) 3 162 (79–295) 197
Unexplained weight loss 148 (84–333) 127 111 (82–205) 6 159 (86–346) 111
(B) PIb
Any symptom 35 (7–92) 2103 41 (13–92) 128 36 (7–93) 1932
Change in bowel habit 42 (14–92) 1106 57 (22–115) 63 42 (14–92) 1023
‘Bleeding from back passage’ 25 (3–69) 607 29 (6–66) 52 24 (3–69) 547
Indigestion/heartburn/persistent tummy ache 31 (5–86) 525 28 (7–90) 27 31 (5–90) 488
Fatigue or tiredness that is unusual for you 31 (7–89) 365 35 (8–65) 26 31 (6–90) 331
Feeling different ‘in yourself’ from usual 30 (4–76) 377 37 (14–65) 21 30 (3–77) 343
Decrease in appetite 20 (3–62) 190 33 (8–90) 15 18 (2–62) 166
Back pain 29 (2–76) 183 41 (37–64) 3 29 (1–88) 172
Unexplained weight loss 31 (5–92) 115 46 (35–73) 4 31 (2–96) 102
(C) HCIb
Any symptom 58 (27–128) 2103 49 (26–106) 128 59 (27–129) 1932
Change in bowel habit 51 (25–99) 1106 47 (28–101) 63 52 (25–99) 1023
‘Bleeding from back passage’ 41 (19–85) 607 37 (20–60) 52 41 (19–86) 547
Indigestion/heartburn/persistent tummy ache 76 (34–156) 525 58 (35–151) 27 78 (34–161) 488
Fatigue or tiredness that is unusual for you 69 (30–146) 365 54 (27–89) 26 70 (29–147) 331
Feeling different ‘in yourself’ from usual 67 (32–139) 377 61 (38–87) 21 69 (30–144) 343
Decrease in appetite 60 (31–138) 190 49 (30–63) 15 64 (30–158) 166
Back pain 88 (35–203) 183 61 (51–461) 3 82 (35–206) 172
Unexplained weight loss 83 (39–191) 115 33 (16–50) 4 89 (43–202) 102
Abbreviations: CRC¼ colorectal cancer; HCI¼ healthcare interval; HSI¼health system interval; IQR, interquartile range; NC¼no cancer; PI¼patient interval; TDI¼ total diagnostic interval.
P-values for CC vs NC with any symptom: (A) TDI P¼ 0.142; (B) PI P¼ 0.606; (C) HSI P¼ 0.078. Similar results were obtained for the comparison between all cancers and NC (data not shown).
aAs these are median time intervals (rather than mean intervals), there is no expectation that the median TDI will equal the sum of median PI and median HSI.
bThe PI and HSI could only be calculated for 2103 participants (unknown presentation date n¼ 213). Those with an available date of presentation had a shorter median TDI (130 days vs 199 days
for the remaining cases).
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symptoms. Although this approach allows us to make robust
comparisons with other findings, it may obscure the finer detail
of symptom patterns and clusters as they evolve over time and
their effects on timely help-seeking by patients and timely
diagnosis in primary and secondary care. Although this was a
large cohort, we had insufficient power to examine specific
clusters of symptoms and their associations with outcomes; a
much larger prospective study would be required to achieve this.
The fact that fewer CRC cases were recruited than was the aim
meant that the study was only powered to detect large differences
in symptoms between those with and without CRC.
This study shows that there are subtle differences in the impact
of symptoms and patient factors on patient and healthcare
intervals, with some clear implications for policy makers and
clinicians. Although rectal bleeding was the only symptom
predictive of CRC in this referred population, it was only reported
as the first symptom in one-third of cases and as a subsequent
symptom in a further 25% of cases. Despite conducting such a
large prospective cohort study, we failed to identify any other
strong solitary symptom signals of CRC, suggesting that bowel
cancer awareness campaigns, which currently concentrate on a
single symptom, should also consider messages that reflect the
importance of multiple symptoms and evolution of symptoms over
time (Moffat et al, 2015). The recently revised NICE guidelines for
early detection of CRC support this premise and have also lowered
the threshold for referral, in line with patient preferences for
investigation (Banks et al, 2014a, b). However, our study has also
shown that only people presenting with shorter histories of rectal
bleeding are investigated promptly, and that healthcare profes-
sionals should remain alert to symptoms of possible CRC in people
with a history of gastro-intestinal or mental health conditions. The
increasingly widespread use of clinical decision support in primary
Table 5. Predictors of TDI, PI and HSI
TDI (n¼2306) PI (n¼2095) HSI (n¼2095)
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Bleeding from back passage 1.79 (1.62–1.98) o0.001 1.41 (1.27–1.57) o0.001 1.56 (1.41–1.72) o0.001
Change in bowel habit 1.55 (1.42–1.69) o0.001 1.04 (0.95–1.13) 0.440 1.55 (1.42–1.70) o0.001
Back pain 0.99 (0.85–1.14) 0.874 1.20 (1.02–1.40) 0.024 0.86 (0.73–1.00) 0.052
Indigestion/heartburn/tummy ache 1.00 (0.90–1.10) 0.942 1.17 (1.06–1.30) 0.003 0.84 (0.76–0.93) 0.001
Decrease in appetite 1.10 (0.95–1.28) 0.200 1.15 (0.98–1.35) 0.087 1.11 (0.94–1.30) 0.224
Weight loss 0.90 (0.75–1.09) 0.284 1.00 (0.82–1.22) 0.987 0.81 (0.66–0.99) 0.038
Fatigue or tiredness 1.14 (1.02–1.27) 0.021 1.11 (0.98–1.25) 0.096 1.04 (0.92–1.17) 0.549
Feeling different 1.21 (1.08–1.35) 0.001 1.25 (1.10–1.41) o0.001 1.01 (0.90–1.14) 0.812
Gender (ref¼ female)
Male 1.01 (0.93–1.10) 0.739 1.03 (0.94–1.13) 0.535 1.02 (0.93–1.11) 0.731
Age at diagnosis (10 years) 1.08 (1.04–1.12) o0.001 1.13 (1.08–1.18) o0.001 0.99 (0.95–1.03) 0.698
IMD (ref¼ least deprived) 0.611 0.645 0.528
Second national quintile 0.98 (0.88–1.09) 1.03 (0.91–1.15) 0.92 (0.82–1.03)
Third national quintile 1.03 (0.90–1.17) 1.09 (0.95–1.25) 0.94 (0.82–1.08)
Fourth national quintile 0.91 (0.79–1.04) 0.97 (0.84–1.12) 0.90 (0.78–1.04)
Fifth national quintile 0.97 (0.83–1.13) 0.98 (0.83–1.16) 0.96 (0.81–1.13)
Gastrointestinal comorbidity 0.80 (0.71–0.89) o0.001 1.01 (0.89–1.14) 0.904 0.78 (0.69–0.88) o0.001
Depression/anxiety 0.86 (0.77–0.96) 0.007 1.05 (0.93–1.18) 0.415 0.80 (0.71–0.90) o0.001
Family History of cancer 0.91 (0.83–0.99) 0.031 0.94 (0.86–1.04) 0.237 0.90 (0.82–0.99) 0.033
Abbreviations: CI¼ confidence interval; HSI¼ health system interval; HR¼hazard ratio; PI¼patient interval; TDI¼ total diagnostic interval. HR estimates are from a flexible parametric survival
multivariable model with only time constant effects. Model is adjusted for all variables in table plus ethnicity (non-White vs White), smoking status (current and ex-smoker vs never), living alone
(yes vs no) and region (North East vs Cambridge). In this context, the HR represents the relative increase in rate of presentation/diagnosis. A HR of 2 would imply that patients in one group
presented/were diagnosed twice as quickly as in the reference group.
Table 6. Time to diagnosis (days) for first symptom/s among CRC group, stratified by stage at diagnosisa
Early stage (n¼64) Late stage (n¼82)
Median (IQR) n Median (IQR) n
Any symptom 157 (93–243) 64 99 (65–198) 83
Change in bowel habit 159 (92–274) 23 111 (65–173) 41
‘Bleeding from back passage’ 92 (36–156) 23 84 (47–133) 28
Indigestion or heartburn or persistent tummy ache that wasn’t normal for you 188 (96–310) 11 103 (62–153) 18
Fatigue or tiredness that is unusual for you 154 (95–226) 15 110 (81–152) 20
Feeling different ‘in yourself’ from usual 114 (95–154) 6 101 (65–153) 18
Decrease in appetite 138 (95–186) 3 83 (56–128) 11
Back pain – 0 98 (92–525) 3
Unexplained weight loss 205 (82–572) 3 69 (39–98) 2
Abbreviations: IQR¼ interquartilerange.
aNot staged: 2.P-values for early vs late stage with any symptom: (i) P¼ 0.019, (ii) P¼ 0.022.
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care can also be informed by our findings (Dikomitis et al, 2015;
Green et al, 2015), but further research is needed, alongside GPs
and specialists, to identify mechanisms by which patients can be
identified, referred and diagnosed in the most timely and
appropriate way.
In conclusion, as efforts to expedite the diagnosis of
symptomatic CRC are likely to have benefits for patients in
terms of improved survival, earlier-stage diagnosis and improved
quality of life, it continues to be a priority to identify symptoms
and other factors, which should prompt an individual to seek help
or a GP to refer in an appropriate and timely manner. It is also
important to develop other strategies for earlier diagnosis,
including increasing uptake of CRC screening and perhaps the
development of biomarkers to improve early detection. Never-
theless, these data provide support for more targeted evaluation
of suspicious symptoms in an attempt to identify CRC at an
earlier and more amenable stage. It may also be that targeted
interventions at higher risk populations aimed at symptom
monitoring could be more effective at recognising symptom
evolution.
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